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Introduction

Abstract  
The present study was designed to assess the role of 5-HT2A/2C
receptors in the acute and repeated effect of clozapine and
olanzapine in a rat conditioned avoidance response model, a
validated model of antipsychotic activity. Male Sprague–Dawley rats that were previously treated with either phencyclidine
(0.5–2.0 mg/kg, sc), amphetamine (1.25–5.0 mg/kg, sc), or saline and tested in a prepulse inhibition of acoustic startle study
were used. They were first trained to acquire avoidance response to a white noise (CS1) and a pure tone (CS2) that differed in their ability to predict the occurrence of footshock.
Those who acquired avoidance response were administered
with clozapine (10.0 mg/kg, sc) or olanzapine (1.0 mg/kg, sc)
together with either saline or 1-2,5-dimethoxy-4-iodo-amphetamine (DOI, a selective 5-HT2A/2C agonist, 1.0 or 2.5 mg/kg,
sc), and their conditioned avoidance responses were tested for
four consecutive days. After two drug-free retraining days, the
long-term repeated effect was assessed in a challenge test during which all rats were injected with a low dose of clozapine
(5 mg/kg, sc) or olanzapine (0.5 mg/kg). Results show that
pretreatment of DOI dose-dependently reversed the acute disruptive effect of clozapine on both CS1 and CS2 avoidance responses, whereas it had little effect in reversing the acute effect of olanzapine. On the challenge test, pretreatment of DOI
did not alter the clozapine-induced tolerance or the olanzapine-induced sensitization effect. These results confirmed our
previous findings and suggest that clozapine, but not olanzapine, acts on through 5-HT2A/2C receptors to achieve its acute
avoidance disruptive effect and likely its therapeutic effects.
The long-term clozapine tolerance and olanzapine sensitization effects appear to be mediated by non-5-HT2A/2C receptors.

In behavioral pharmacology, the conditioned avoidance response (CAR) model is routinely used as a preclinical test for antipsychotic activity (Arnt 1982). In
a typical experiment, a rat is placed in a two-compartment shuttle box and presented with a neutral conditioned stimulus (CS) such as a light or tone, followed
by an aversive unconditioned stimulus (US), such as a
footshock. The animal may escape the US by running
from one compartment to the other. However, after several presentations of the CS–US pairing, the animal typically runs during the CS and before the onset of the US,
thereby avoiding the US altogether. Rats acutely treated
with low doses (non-cataleptic) of antipsychotic drugs
(APDs) often fail to acquire or perform avoidance responses to the CS, whereas their escape responses to the
US are less affected (Ader and Clink 1957; Wadenberg
and Hicks 1999). This feature is shared by all clinically
approved antipsychotic drugs, but not by anxiolytics or
antidepressants (Mead et al. 2008; Sun et al. 2010).
In recent years, we have expanded the use of this
model to study the behavioral and neurochemical mechanisms of action of antipsychotic drugs (Li et al. 2007,
2009a, b, 2010; Mead and Li 2010). We also focus on the
long-term (repeated) effect of antipsychotic treatment.
One interesting finding comes from our recent study (Li
et al. 2010). In this study, we compared the acute and repeated effects of clozapine and olanzapine, two atypical
antipsychotic drugs. We found that although acute administration of both drugs produces a similar disruptive
effect on conditioned avoidance responding, repeated
administration of clozapine produces a tolerance-like ef-

Keywords:  Clozapine, Olanzapine, 2,5-Dimethoxy-4-iodoamphetamine, Repeated antipsychotic treatment, D2/3 receptor, 5-HT2A/2C receptor, Conditioned avoidance response, Sensitization, Tolerance
497

498

Li, Sun, & Mead

fect (i.e. a gradual decrease in disrupting avoidance over
time), whereas repeated administration of olanzapine
produces a sensitization-like effect (a gradual increase
in disrupting avoidance over time). We also showed
that pretreatment of 1-2,5-dimethoxy-4-iodo-amphetamine (DOI, a selective 5-HT2A/2C agonist, 2.5 mg/kg,
sc), but not quinpirole (a selective dopamine D2/3 agonist, 1.0 mg/kg, sc), attenuated the acute clozapine-induced disruption of avoidance responding, whereas
pretreatment of quinpirole, but not DOI, attenuated that
effect of olanzapine. On the repeated effects, pretreatment of DOI had no effect on either clozapine-induced
tolerance or olanzapine-induced sensitization. In contrast, pretreatment of quinpirole attenuated the potentiated disruption of olanzapine, but enhanced the tolerance-like effect of clozapine. Based on these findings
on doubly dissociated receptor mechanisms, we suggest
that acute clozapine disrupts avoidance response primarily by blocking 5-HT2A/2C receptors, whereas acute
olanzapine appears to exert its disruptive effect primarily by blocking dopamine D2 receptors. Both clozapine-induced tolerance and olanzapine-induced sensitization are likely mediated by D2/3 receptor, but not by
5-HT2A/2C receptor.
Because olanzapine, like clozapine, also possesses
a potent antagonism on the 5-HT2A/2C receptor in addition to a relatively weak antagonism on D2 receptor
(Meltzer et al. 2003), it is thus surprising that 5-HT2A/2C
receptor is not found to be involved in the acute effect
of olanzapine and it does not seem to play little role
in the repeated effects of both drugs. These behavioral
and neurochemical similarities and differences between the acute and repeated effects of clozapine and
olanzapine warrant further investigation. The present study was designed to further assess the role of the
5-HT2A/2C receptor in the acute and repeated effect of
clozapine and olanzapine to ensure that our previous
findings are not artifacts and can be generalized to different animals and across different testing conditions.
In the present study, we used heterogeneous groups of
animals that had prior experience with either amphetamine, phencyclidine (PCP), or saline, as opposed to
normal drug-naïve animals. These amphetamine- and
PCP-pretreated rats had been shown to exhibit a deficit in the prepulse inhibition (PPI) of acoustic startle
(Li et al. 2011), one of the most studied cognitive deficits associated with schizophrenia. Thus, they could
be considered as putative “schizophrenic-like” animals
(Geyer et al. 2001; Russig et al. 2003). In addition, we
used a modified CAR paradigm involving two types of
CS (CS1: a white noise and CS2: a pure tone), as opposed to just the CS1 used in our previous work (Li
et al. 2010). We created these two types of CS signals
that varied in their motivational salience (e.g. ability to
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elicit avoidance) and ability to predict the occurrence
of an US footshock. This was achieved by pairing the
CS1 with the US in every CS1 trial while pairing the
CS2 with the US in only half of the CS2 trials if the rats
failed to respond. This novel paradigm provides an additional measure of antipsychotic drug treatment on
avoidance responding. We have used this paradigm to
examine the behavioral mechanisms of antipsychotic
action (Li et al. 2009b; Zhang et al. 2011) and aberrant
behavioral responding in animal models of schizophrenia (Li et al. 2008; Chen et al. 2011).
Materials and methods
Animals
Subjects were male Sprague–Dawley rats (226–250 g
upon arrival) purchased from Charles River Inc. (Portage, MI). They had been used in a separate study in
which they were repeatedly treated with either amphetamine (1.25–5.0 mg/kg), PCP (0.5–2.0 mg/kg) or vehicle and tested for PPI of acoustic startle response once
daily for six consecutive days (Li et al. 2011). None of
them had any antipsychotic drug experience prior to
this study and there was at least a 2-week interval between the last amphetamine or PCP experience and the
first antipsychotic treatment. Rats were housed two per
cage, in 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages under 12-h light/dark conditions (light
on between 6:30 a.m. and 6:30 p.m.). Room temperature
was maintained at 22 ± 1°C with a relative humidity of
50–60%. Food and water were available ad libitum. Animals were allowed at least 1 week of habituation to
the animal facility before being used in experiments.
All procedures were approved by the Institutional Animal Care and Use Committee at the University of
Nebraska–Lincoln.
Two-way avoidance conditioning apparatus
Eight identical two-way shuttle boxes custom designed and manufactured by Med Associates (St.
Albans, VT) were used. Each box was housed in
a ventilated, sound-insulated isolation cubicle
(96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was
64 cm long, 30 cm high (from grid floor), and 24 cm
wide, and was divided into two equal-sized compartments by a partition with an arch style doorway (15 cm
high × 9 cm wide at base). A barrier (4 cm high) was
placed between the two compartments, so the rats had
to jump from one compartment to the other. The grid
floor consisted of 40 stainless-steel rods with a diameter of 0.48 cm, spaced 1.6 cm apart center to center,
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through which a scrambled footshock (US, 0.8 mA,
maximum duration 5 s) was delivered by a constant
current shock generator (Model ENV-410B) and scrambler (Model ENV-412). Illumination was provided by
two houselights mounted at the top of each compartment. The conditioned stimuli (either a 76 dB white
noise CS1 or a 85 dB 2,800 Hz pure tone CS2) were produced by a speaker (ENV 224 AMX) mounted on the
ceiling of the cubicle, centered above the shuttle box.
Background noise (approximately 74 dB) was provided
by a ventilation fan affixed at the top corner of each
isolation cubicle. All training and testing procedures
were controlled by Med Associates programs running
on a computer.
Drugs
Clozapine (CLZ) and olanzapine (OLZ) (gifts from
NIMH drug supply program) were dissolved in 1.0%
glacial acetic acid in distilled water. DOI (RBI-Sigma,
Natick, MA) was dissolved in 0.9% saline. All drugs
were administered subcutaneously in a volume of
1.0 ml/kg body weight. Choices of drug doses for CLZ
and OLZ were based on our previous studies showing that at the chosen doses; both produce a reliable
and comparable disruption of avoidance responding
(Li et al. 2004a, 2009a, b, 2010; Mead and Li 2010), and
they give rise to clinical levels of striatal D2 occupancy
(50–80%) at these doses (Kapur et al. 2003). The doses
of DOI were chosen based on our recent work showing
that DOI at 2.5 mg/kg reversed the avoidance-disruptive effect (Li et al. 2010) and the maternal-disruptive effect of clozapine (Zhao and Li 2009). Previous work also
showed that DOI produces maximal behavioral effects
between 2 and 3 mg/kg (Schreiber et al. 1995; Granoff
and Ashby 1998; Halberstadt et al. 2009).
Experiment 1: Effects of DOI pretreatment on
clozapine-induced CS1 and CS2 avoidance disruption
Sixty rats previously used in the PPI study (Li et al.
2011) were used in this experiment. In that study, one
group of rats (n = 12) was repeatedly injected with saline and tested for PPI daily for six consecutive days.
The second group (n = 12) was repeatedly injected with
4.0 mg/kg amphetamine for six consecutive days. The
third group was injected with 1.25 mg/kg amphetamine on day 1–2, 2.5 mg/kg on day 3–4, and 5.0 mg/
kg on day 5–6. The fourth group was repeatedly injected
with 2.0 mg/kg phencyclidine throughout the six consecutive days. Last, the fifth group was injected with
0.5 mg/kg phencyclidine on day 1–2, 1.0 mg/kg on day
3–4 and 2.0 mg/kg on day 5–6.
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Thirteen days after the last PPI test, all rats were
trained in the modified two-way avoidance conditioning task for a total of ten sessions over a 2-week period. Each training session consisted of 30 trials. Ten
trials (CS1 trials) used a 10-s 76-dB white noise as the
CS with its termination immediately followed by the
shock (0.8 mA, maximum duration 5 s) if the rats did
not make an avoidance response. The remaining 20
trials (CS2 trials) used a pure tone (10 s, 2,800 kHz,
85 dB) as the CS. In ten CS2 trials, the CS2 was followed by the shock if the rat failed to respond to the
CS2, whereas, in another ten trials, there was no shock
following the CS2. The ten CS1 trials were randomly
intermixed with the 20 CS2 trials. During each trial, if
a subject moved from one compartment into the other
within the 10-s CS presentation, that CS was immediately terminated, the shock was prevented, and this
shuttling response was recorded as avoidance (termed
CS1 avoidance or CS2 avoidance). If the rat remained
in the same compartment for more than 10 s and made
a crossing upon receiving the footshock, this response
was recorded as escape. If the rat did not respond during the entire 5-s presentation of the shock, the trial
was terminated and escape failure was recorded. At
the end of training session, 46 rats had reached training criterion (≥7 CS1 avoidances and at least one CS2
avoidance in the last two training sessions: mean number of CS1 avoidance = 9.39 + 0.13 and mean number
of CS2 avoidance = 13.09 + 0.59). We did not find any
prior amphetamine or PCP treatment effect on the acquisition of CS1 avoidance (F(4, 55) = 1.131, p = 0.351)
or CS2 avoidance (F(4, 55) = 1.592, p = 0.189). The welltrained rats were then randomly assigned to one of
four groups: VEH + VEH (n = 11, saline + sterile water), VEH + CLZ (n = 12), DOI−1.0 mg/kg + CLZ
(n = 12), and DOI−2.5 mg/kg + CLZ (n = 11), and
tested daily under the CS-only condition (no shock,
ten CS1 trials, and 20 CS2 trials) for four consecutive
days. During each test, rats were first pretreated with
DOI 1.0 mg/kg, 2.5 mg/kg (sc) or saline followed by
an injection of sterile water (VEH), or CLZ 10.0 mg/
kg (sc) 10 min later. Thirty minutes after the second injection, rats were placed in the CAR boxes and tested.
One day after the last drug test, all rats were tested
drug-free for one session under the CS-only (no shock)
condition and retrained for one session under the CS–
US condition to bring their avoidance back to the predrug level. A final drug challenge test was conducted
24 h after the retraining session to assess the long-term
effect of repeated antipsychotic treatment on avoidance. During the test, all rats were injected with CLZ
5.0 mg/kg and tested 1 h later in the same CAR procedure as used in the drug testing phase.
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Experiment 2: Effects of DOI pretreatment on
olanzapine-induced CS1 and CS2 avoidance
disruption
Thirty-six rats previously used in a PPI study were
used in this experiment. Among them, 12 rats were repeatedly injected with saline and tested for PPI daily
for six consecutive days. The second group (n = 12)
was repeatedly injected with 0.5 mg/kg phencyclidine and the third group (n = 12) was repeatedly injected with 1.0 mg/kg phencyclidine and tested for
PPI daily for six consecutive days. Eighteen days after
the last PPI test, rats were trained in the modified CAR
task for ten sessions. At the end of the training phase,
29 rats reached the training criterion (mean number of
CS1 avoidance = 9.10 + 0.21 and mean number of CS2
avoidance = 13.28 + 0.64), and their prior drug experience was not a factor in the acquisition of CS1 avoidance (F(2, 33) = 1.551, p = 0.227) or CS2 avoidance (F(4,
55) = 2.047, p = 0.145). Rats were then randomly assigned to the following three groups: VEH + VEH (saline + sterile water, n = 9), VEH + OLZ (1.0 mg/kg,
n = 10), and DOI−2.5 mg/kg + OLZ (1.0 mg/kg, n = 10),
and were subjected to four sessions of drug testing, two
sessions of drug-free testing/retraining and a final drug
challenge test, following the exact same schedule as described in “Experiment 1”. During the challenge test, all
rats were injected with OLZ 0.5 mg/kg.
Statistical analysis
Avoidance response data were expressed as
mean ± SEM. Data on the four drug test sessions were
analyzed using a repeated measures analysis of variance (ANOVA) with the between-subjects factor being the treatment (group) and the within-subjects factor being test session. Data for CS1 and CS2 avoidance
were analyzed separately. Individual one-way ANOVAs followed by Tukey post hoc tests were used to detect group differences on each drug test session and the
final challenge session. A conventional two-tailed level
of significance at the 5% level was used.
Results
Experiment 1: effects of DOI pretreatment on clozapineinduced CS1 and CS2 avoidance disruption
As can be seen in Figure 1, CLZ treatment suppressed
CS1 and CS2 avoidance responses throughout the four
drug test sessions. Pretreatment of DOI dose-dependently reversed this effect of CLZ, and the DOI reversal

Figure 1. Effects of pretreatment of DOI on acute clozapineinduced disruption of CS1 avoidance (a) and CS2 avoidance
(b). Mean (+SEM) numbers of avoidance responses of the four
groups of rats on the last CAR training day (pre-drug), four
drug test days (Day 1 to Day 3), and two drug-free test days
(drug-free CS-only and drug-free retraining). *p < 0.05 significantly different from the VEH + VEH group; #p < 0.05 significantly different from the VEH + CLZ group

effect tended to decrease over the drug test sessions. Repeated-measures ANOVA on the number of CS1 avoidance indicated a main effect of group, F(3, 42) = 24.008,
p < 0.001, session, F(3, 126) = 6.318, p = 0.001, and a significant interaction between group and test session, F(9,
126) = 2.223, p = 0.025. For the CS2 avoidance, repeated
measures ANOVA also revealed a main effect of group,
F(3, 42) = 27.353, p < 0.001, session, F(3, 126) = 3.721,
p = 0.013, and a significant interaction between group
and test session, F(9, 126) = 1.978, p = 0.047.
One-way ANOVAs followed by Tukey post hoc tests
were used to examine group differences on each drug
test session. On the CS1 avoidance, the VEH + CLZ
group differed significantly from the VEH + VEH group
on every drug day (all ps < 0.001). It also differed significantly from the DOI−2.5 + CLZ group on day 1,
p < 0.001 and day 2, p = 0.019, and differed significantly
from the DOI−1.0 + CLZ group on day 1, p = 0.020. On
the CS2 avoidance, the VEH + CLZ group differed significantly from the vehicle group on every drug day (all
ps < 0.001), but it only differed significantly from the
DOI−2.5 + CLZ group on day 1, p < 0.003. Overall, re-
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sults from the drug test phase suggest that pretreatment
of DOI dose-dependently reversed the CLZ-induced
disruption of avoidance responding. This reversal effect
was transient in nature and tended to diminish with repeated drug administration. It also showed a preferential action against CLZ disruption on CS1 avoidance (a
response to a more salient stimulus) over CS2 avoidance
(a response to a less salient stimulus).
On the two drug-free sessions, there was no significant group effect on either CS1 or CS2 avoidance (all
ps > 0.412). However, on the drug challenge test during
which all rats were acutely injected with CLZ at 5.0 mg/
kg (Figure 2), those that were previously treated with
CLZ only (i.e. the VEH + CLZ rats) made more avoidance responses than the vehicle rats treated with CLZ
for the first time, indicating that prior CLZ treatment
caused a decreased response to CLZ (a tolerance effect).
One-way ANOVA revealed a main effect of group on
the CS1 avoidance, F(3, 42) = 2.936, p = 0.044, and the
CS2 avoidance F(3, 42) = 3.072, p = 0.038. Post-hoc tests
indicated that the VEH + CLZ group differed significantly from the VEH + VEH group on the CS2 avoidance, p = 0.033. Pretreatment of DOI failed to alter the
tolerance effect of repeated CLZ treatment, as there was
no significant group difference between the VEH + CLZ
group and the other two DOI pretreated groups (all
ps > 0.0128).
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Figure 2. Effects of pretreatment of DOI on the repeated treatment effect of clozapine on CS1 and CS2 avoidance responses.
Data are mean (+SEM) numbers of avoidance responses on the
challenge test day. Rats that were previously treated with double vehicles, vehicle plus clozapine (10.0 mg/kg), or DOI (1.0
or 2.5 mg/kg) plus clozapine (10.0 mg/kg) were challenged
with clozapine (5.0 mg/kg). *p < 0.05 significantly different
from the corresponding VEH + VEH group

Experiment 2: effects of DOI pretreatment on
olanzapine-induced CS1 and CS2 avoidance disruption
OLZ 1.0 mg/kg suppressed avoidance response on
the first drug day and progressively enhanced its suppression over the 4-day drug test period (Figure 3). The
disruptive effect of OLZ did not seem to be affected
by pretreatment of DOI. Repeated measures ANOVA
on the number of CS1 avoidance indicated a main effect of group, F(2, 26) = 198.946, p < 0.001, session, F(3,
78) = 7.238, p < 0.001, and a significant interaction between group and test session, F(6, 78) = 4.797, p < 0.001.
For the CS2 avoidance, repeated measures ANOVA
also revealed a main effect of group, F(2, 26) = 41.160,
p < 0.001, session, F(3, 78) = 12.223, p < 0.001, and a significant interaction between group and test session, F(6,
78) = 2.620, p = 0.023.
One-way ANOVAs followed by Tukey post hoc tests
revealed that the two OLZ groups (i.e. VEH + OLZ and
DOI−2.5 + OLZ) did not differ from each other on both
the CS1 and CS2 avoidances (all ps > 0.498), but differed
significantly from the VEH + VEH group on every drug
day (all ps < 0.001), suggesting that pretreatment of DOI
was ineffective in reversing the OLZ-induced disruption
of avoidance responding.
On the first drug-free test session, avoidance responses to CS1 and CS2 in the two OLZ-treated groups

Figure 3. Effects of pretreatment of DOI on acute olanzapineinduced disruption of CS1 avoidance (a) and CS2 avoidance
(b). Mean (+SEM) numbers of avoidance responses of the four
groups of rats on the last CAR training day (pre-drug), four
drug test days (Day 1 to Day 3), and two drug-free test days
(drug-free CS-only and drug-free retraining). *p < 0.05 significantly different from the VEH + VEH group

recovered to some extent, but not to the level comparable to that of the vehicle. There was a main effect of
group for the CS1 avoidance, F(2, 26) = 10.554, p < 0.001,
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and the CS2 avoidance, F(2, 26) = 4.738, p = 0.018. Post
hoc tests showed that the VEH + OLZ group differed
significantly from the VEH + VEH group on both types
of avoidance (CS1: p < 0.001; CS2: p = 0.014), whereas
the DOI−2.5 + OLZ group differed significantly from
the VEH + VEH only on the CS1 avoidance (p = 0.016),
but not on the CS2 avoidance (p = 0.146). On the second drug-free retraining session, there was still a main
effect of group for the CS2 avoidance, F(2, 26) = 4.462,
p = 0.022. Post hoc tests showed that the VEH + OLZ
group differed significantly from the VEH + VEH group
on the CS2 avoidance (p = 0.026).
On the drug challenge test during which all rats were
acutely injected with OLZ at 0.5 mg/kg (Figure 4), rats
previously treated with VEH + OLZ or DOI−2.5 + OLZ
made fewer avoidances than the VEH + VEH rats, indicating a strong sensitization-like effect of repeated OLZ
treatment. One-way ANOVA revealed a main effect of
group on the CS1 avoidance, F(2, 26) = 9.329, p = 0.001,
and the CS2 avoidance F(2, 26) = 6.662, p = 0.005. Posthoc tests indicated that VEH + OLZ and DOI−2.5 + OLZ
groups all differed significantly from the VEH + VEH
group on the CS1 and CS2 avoidance (all ps < 0.013),
suggesting that pretreatment of DOI failed to alter the
long-term OLZ sensitization effect.
Discussion
The present study further demonstrated an interesting dissociated serotonin receptor mechanism underlying acute and repeated effects of clozapine and olanzapine on avoidance responding. On the acute effect
side, we observed that pretreatment of DOI dose-dependently reversed the clozapine-induced disruption,
but had no effect on olanzapine-induced one. On the repeated effect side, we confirmed that repeated administration of clozapine produces a tolerance-like effect,
whereas repeated administration of olanzapine produces a sensitization-like effect. Importantly, pretreatment of DOI failed to alter both effects, suggesting that
5-HT2A/2C receptor is not likely to be involved in the repeated effects of clozapine and olanzapine.
The modified CAR paradigm was utilized in the
present study to verify the receptor mechanisms of clozapine and olanzapine as identified in our previous report (Li et al. 2010) and to ensure our finding is not the
artifact of any specific CAR setup. Despite the procedural difference, we still observed that pretreatment of
DOI dose-dependently reversed clozapine-induced disruption of avoidance but had no effect on olanzapineinduced disruption, a finding consistent with our previous work (Li et al. 2010) in which we only used one
avoidance response (CS1). We did notice two slightly
different findings between the present clozapine study
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Figure 4. Effects of pretreatment of DOI on the repeated
treatment effect of olanzapine on CS1 and CS2 avoidance responses. Data are mean (+SEM) numbers of avoidance responses on the challenge test day. Rats that were previously
treated with double vehicles, vehicle plus olanzapine (1.0 mg/
kg), or DOI (2.5 mg/kg) plus olanzapine (1.0 mg/kg) were
challenged with olanzapine (0.5 mg/kg). *p < 0.05 significantly
different from the corresponding VEH + VEH group

and the previous one. One is that the reversal effect of
DOI 2.5 mg/kg seems stronger and more complete than
the effect found in the previous study. For example,
on the first drug day, the mean number of CS1 avoidance in the DOI−2.5 + CLZ group was 86% of that in
the VEH + VEH group in the present study, whereas it
was only 46% of the VEH + VEH in the previous study.
The second difference is that the DOI’s reversal effect
diminished over the test sessions in the present study,
whereas it remained stable in the previous study. These
results suggest that although specific parameters used
in a CAR procedure may not be critical in revealing the
neuroreceptor mechanisms of action of antipsychotic
drugs, they could influence the direction and magnitude of the behavioral effects of drugs, a phenomenon
best known as the “rate-dependent drug effects” (Dews
1976; Spealman et al. 1983; Barrett 2002; McMillan and
Katz 2002; Barrett and Bergman 2008). The present finding, together with our previous maternal behavior studies in which we showed that pretreatment of DOI, but
not quinpirole, dose-dependently reversed the clozapine-induced disruption of rat maternal behavior (Zhao
and Li 2009, 2010), provides a strong support that clozapine achieves its behavioral effects mainly by blocking 5-HT2A/2C receptors.
Because olanzapine, like clozapine, has a potent antagonist action on 5-HT2A/2C receptors, it is somewhat surprising to see this dissociated DOI effect on these drugs.
However, it should be noted that olanzapine has a much
lower 5-HT2A/2C affinity, but a much higher D2 receptor
affinity than clozapine (Meltzer et al. 2003). Furthermore,
olanzapine has a slower dissociation rate (k off value)
from the D2 receptor than clozapine (Kapur and Seeman
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2001). More importantly, its D2 receptor occupancy predicts its clinical effect better than its 5-HT2A/2C receptor
occupancy (Kapur et al. 1999, 2000). These differences
in molecular mechanisms of action may explain the differences between olanzapine and clozapine in response
to the DOI pretreatment. Because olanzapine’s D2 occupancy correlates well with its disruptive effect on avoidance response (Wadenberg et al. 2001; Olsen et al. 2008),
it is thus likely that olanzapine’s avoidance disruptive effect is mainly mediated by its action on D2 receptor but
not on 5-HT2A/2C receptor. Our previous finding that pretreatment of quinpirole, a selective dopamine D2/3 agonist attenuates the acute olanzapine-induced disruption
of avoidance response is consistent with this hypothesis. The lack of involvement of 5-HT2A/2C receptors in the
avoidance-disruptive effect of olanzapine is also consistent with human brain imaging work suggesting that for
olanzapine, D2 receptor occupancy alone can explain its
antipsychotic effect (Kapur et al. 1999).
Because clozapine has a dual action on both 5-HT2A
and 5-HT2C receptors, and DOI is nonselective for
5-HT2A versus 5-HT2C receptors, it is not certain which
serotonin receptor is responsible for DOI’s reversal effect and the avoidance disruptive effect of clozapine. As
we have discussed earlier (Li et al. 2010), we speculate
that the 5-HT2A, but not 5-HT2C receptor, may be more
important. This idea is supported by the findings that
selective 5-HT2C receptor agonists are generally ineffective in counteracting clozapine (Ichikawa et al. 2001),
and many behavioral and molecular effects of DOI are
found to be mediated by its antagonism on 5-HT2A receptors, and not on 5-HT2C receptors (Schreiber et al.
1995; Sipes and Geyer 1995, 1997; Smith et al. 2003; Halberstadt et al. 2009). Future work using more selective
5-HT2A and 5-HT2C receptor agonists may help determine the relative contribution of these two serotonin receptor subtypes in the mediation of the avoidance disruptive effect of clozapine. Clozapine has high affinity
for adrenergic α1 receptor, muscarinic M1 receptor, and
histamine H1 receptor and moderate affinity for the D4
and 5-HT6 receptors, its actions on these receptors may
also contribute to its avoidance-disruptive effect.
In our previous study, we have used a similar modified CAR paradigm to examine the motivational salience attenuation action of antipsychotic treatment (Li
et al. 2009b; Zhang et al. 2011). We found that olanzapine and risperidone disrupt the CS2 (a less salient conditioned stimulus) avoidance to a greater extent than the
CS1 avoidance. Although it was not the focus of the current study, the preferential action against the CS2 avoidance over the CS1 avoidance by olanzapine and clozapine was also apparent. For example, on the first drug
test day, the VEH + CLZ rats made 12.5% CS1 avoidance, but only 4.17% CS2 avoidance. Similarly, the
VEH + OLZ rats made 23% CS1 avoidance but 19% CS2
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avoidance. Another piece of supporting evidence was
that the impaired CS1 avoidance in the VEH + OLZ
group recovered completely on the drug-free retraining
session, while the CS2 avoidance did not. Finally, the reversal effect of DOI pretreatment on clozapine-induced
CS1 disruption lasted longer (2 days) than its effect on
CS2 disruption (1 day), indirectly reflecting the stronger and preferential action of clozapine against the CS2
avoidance over the CS1 avoidance. This finding may explain that antipsychotic drugs achieve their clinical effects on psychosis by selectively attenuating the motivational salience of psychotic thoughts and perception (Li
et al. 2004b, 2007).
The present study further confirmed the existence
of a clozapine-induced tolerance effect and an olanzapine-induced sensitization effect in the CAR model. This
kind of repeated effect is evidenced by the finding that
the VEH + CLZ rats made significantly more avoidance responses, and the VEH + OLZ rats made significantly fewer avoidance responses than the VEH + VEH
rats in the drug challenge test (Li et al. 2007, 2009a, 2010;
Mead and Li 2010). Consistent with our previous findings, pretreatment of DOI did not alter both types of repeated effects, indicating that the long-term effects of
clozapine and olanzapine are not mediated by their actions on the 5-HT2A/2C receptor system. In our previous
study, we showed that pretreatment of quinpirole attenuated olanzapine-induced sensitization effect, but potentiated clozapine-induced tolerance, suggesting that
the repeated effect of clozapine and olanzapine may be
commonly mediated by their action on the D2/3 receptor system (Atkins et al. 1999; Kapur et al. 2003; MoranGates et al. 2006). Overall, findings from the previous
study and the present one collectively revealed dissociated dopamine and serotonin receptor systems underlying the acute and repeated effects of clozapine and olanzapine. One important future project is to delineate the
neuroadaptive changes induced by repeated antipsychotic treatment that are mediated by these and other
receptor systems (e.g. 5-HT1A, D1, D4, etc.) and identify
their clinical relevance.
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